Hormones & Hair Loss: Why Male and Female Pattern Loss Need Different Treatment

Part of the PRO EXO Professional Series — clinical-grade exosome vials for hair transplant surgeons, dermatologists, and aesthetic clinics.

Pattern hair loss looks similar across patients — thinning, reduced density, scalp showing through — but the biology underneath is not the same in everyone. The clearest fault line runs between the sexes. Male and female pattern loss share a final common pathway of follicular miniaturisation, yet they are driven by different hormonal signals, present in different patterns, and respond to different combinations of therapy. Any serious male vs female pattern hair loss treatment approach has to start there — because a protocol, and a product, that ignores the difference will under-serve half the caseload.

It is easy to lose this distinction. Both sexes end up with thinner, finer, fewer hairs, and both are described with the same word, “androgenetic.” But that shared label hides two genuinely different hormonal problems, and the treatment implications are real — including which in-clinic exosome vial you should reach for.

This guide sets out the hormonal basis of the two presentations for a clinical audience, then explains why it has direct consequences for how you choose an in-clinic exosome vial. It assumes a professional setting and is not a substitute for individual medical judgement or, where indicated, systemic prescribing.

The hormonal basis of androgenetic alopecia

Androgenetic alopecia (AGA) is hormonally mediated and genetically predisposed — but the hormonal story differs by sex. In men, the dominant driver is dihydrotestosterone (DHT), converted from testosterone by the enzyme 5-alpha-reductase. Genetically susceptible follicles in the frontal and vertex scalp carry the androgen sensitivity; under DHT influence they progressively shorten the growth (anagen) phase and miniaturise over successive cycles, producing finer, shorter, less pigmented hairs until the follicle is effectively dormant. The occipital fringe is spared because those follicles are androgen-independent — the same biological fact that makes the donor region viable for transplantation.

In women, the picture is more complex and less purely androgenic. Female pattern loss usually presents as diffuse thinning over the crown with a preserved frontal hairline — the widening central part rather than the receding temples of the male pattern. Androgen sensitivity still contributes, but the female hormonal environment matters just as much: estrogens appear to exert a protective, growth-favouring influence on the follicle, and the decline in estrogen around menopause is commonly associated with accelerated thinning. Many women date the change to that window.

So the same word, “androgenetic,” hides two different hormonal problems: a DHT-led process in men, and a shifting estrogen-to-androgen balance in women. That divergence is not academic — it is the reason male vs female pattern hair loss treatment cannot run off a single script, from assessment through to product choice.

The pattern and pathway diverge too

The hormonal difference expresses itself in everything downstream. Men are staged on the Norwood-Hamilton scale and typically present with temporal recession and vertex thinning; women are staged on Ludwig or Sinclair scales and present diffusely. Female cases warrant closer screening for contributing factors — thyroid function, iron status, and the peri-menopausal transition among them — before a pathway is fixed, because more of the female picture is potentially reversible or multifactorial.

Crucially, some of the systemic options that anchor male AGA management are unsuitable in women, whether by contraindication, reproductive-safety considerations, or preference. That narrows the female toolkit and makes non-systemic, in-clinic options disproportionately valuable — which is precisely where a well-chosen exosome vial earns its place for women who cannot or will not use certain medications.

Why one-size-fits-all exosomes fall short

Exosome scalp therapy has moved from research into routine clinical use, and it is a genuinely useful adjunct — the perifollicular signalling it supports suits a miniaturising follicle. But most of the market supplies a single, generic vial: one formula marketed to every patient regardless of sex, age, or driver.

If the male and female follicular environments differ hormonally, the ideal supportive blend is unlikely to be identical for both. A generic vial is, by design, a compromise — optimised for neither presentation, applied to both because it is simpler to manufacture and sell. Treating a two-sided problem as if it had one side is a clinical shortcut.

For a clinic it is also a competitive weakness. When every supplier offers effectively the same vial, there is nothing to differentiate the treatment a clinic provides — and nothing to explain to a patient beyond price. A sex-specific exosome approach changes that conversation entirely.

OSSOME’s differentiation: a sex-specific base

Ossome’s MINOX PRO EXO range is built around the male–female split rather than around a single formula, with dedicated Men and Fem bases so the clinician matches the vial to the patient’s sex and pattern instead of applying one generic blend to everyone. The range also segments on a second axis — the underlying driver and the patient’s age:

MINOX PRO EXO Gen (Men / Fem) is formulated for genetic hair loss — androgenetic alopecia, the hormonal pattern process described above — and maps to a standard AGA protocol.

MINOX PRO EXO Envigro (Men / Fem) is formulated for environmental hair loss, mainly in younger patients (teens to early twenties), with an age-appropriate blend distinct from the adult-AGA formulation.

The result is a small matrix — genetic vs environmental, male vs female — where competitors offer a single point. The differentiation is not a marketing layer added on top; it is present in the base itself. That is the strongest thing a clinic can say about the treatment it provides: the exosome your patient receives is chosen for their specific presentation, not handed out identically to everyone who walks in. And a note on how the range is positioned, because it matters clinically — not on exosome count, which is a marketing metric rather than a clinical one, but on purity, quality, and blend composition, from a plant-derived source that is the most ethical and legal option for scalp use.

The homecare foundation is the same for both

Personalisation belongs in the in-clinic base; the daily homecare does not need to be sex-specific, and Ossome’s is deliberately universal — the MINOX Root Reactivator Shampoo, Scalp Reactivating Serum, and Smooth Operator Conditioner form one supportive regimen for all scalp types, used by male and female patients alike.

This is the integrated part of the offer: the in-clinic vial delivers sex-matched regenerative support during treatment sessions, while the universal homecare maintains scalp condition between visits and after the induction course. A clinic that sends the patient home with nothing relies entirely on spaced in-clinic sessions to hold a chronic, progressive condition — whereas one that pairs the right in-clinic vial with a consistent daily regimen is treating the follicle continuously. Personalised where it counts, consistent everywhere else.

Matching the patient to the vial

A framework, not a fixed prescription. Exosome therapy is an adjunct; efficacy in AGA is emerging and complements established medical management.

What this means for the clinic

Treating male and female pattern loss as one condition is the most common way a hair service leaves results — and differentiation — on the table. The hormonal biology is different, so the assessment forks, the medical options differ, and the in-clinic exosome base should differ too. A clinic that can explain why the woman in the chair receives a different vial from the man before her is offering something a generic-exosome competitor cannot. Sound male vs female pattern hair loss treatment is not about a single breakthrough vial — it is about matching the right regenerative base to the right driver, and backing it with a consistent daily foundation. That is the design intent behind Ossome’s sex-specific PRO EXO MINOX range.

Frequently asked questions

Why do men and women need different hair-loss treatment? Because the hormonal driver differs. Male pattern loss is DHT-led on androgen-sensitive follicles; female pattern loss involves androgen sensitivity plus a shifting estrogen-to-androgen balance, with estrogen decline around menopause a common factor. Different biology means different assessment, different medical options, and — in the Ossome system — a different in-clinic base.

Can the same exosome vial be used for both sexes? A generic one is applied that way, but it is a compromise optimised for neither. Ossome’s MINOX PRO EXO uses dedicated Gen Men and Gen Fem bases so the vial is matched to the presentation rather than shared.

What is the difference between Gen and Envigro? Gen is formulated for genetic (androgenetic) pattern loss; Envigro is an age-appropriate blend for environmental, mainly younger-onset hair loss. Both come in Men and Fem versions.

Is the homecare different for men and women? No — the daily MINOX homecare regimen is universal. Personalisation lives in the in-clinic vial; the homecare is the consistent daily foundation for both.

Related clinical guides

Female Pattern Hair Loss: A Clinic Treatment Approach →

Male Pattern Hair Loss: A Clinic Treatment Approach →

Androgenetic Alopecia: A Clinic Treatment Protocol →

Exosomes vs PRP for Hair Loss: What the Evidence Shows Clinicians →